We have established a computerized data bank to store, retrieve and analyze an extensive collection (26 years/ greater than 200 patients) of epidemiological, clinical and laboratory information about the systemic vasculitides. We have continued to study the efficacy of daily low dose cyclophosphamide CP and prednisone as remission inducing and potentially curative therapy in systemic vasculitis. The long-term toxicity of daily CP therapy in some patients has led to studies of alternative treatment including (1) intermittent intravenous high dose CP, and (2) weekly low dose methotrexate (3) daily trimethoprim/sulfamethoxazole in limited Wegener granulomatosis (WG) and high dose intermittent intravenous immunoglobulin. We have evaluated various surgical interventions for the treatment of upper airway disease in WG. We have studied the sensitivity, specificity and prognostic value of the antineutrophil cytoplasmic antibody to determine its utility as a guide to therapy in WG. Because the vasculitides are rare disorders, clinical research has been limited by the inability of any single institution to recruit large numbers of patients. To address this issue we have organized an 8 site Multi-Center Collaborative Network that will address problems relating to epidemiology and treatment trials. The pathogenesis of the vasculitides has been investigated in vitro with the aid of endothelial cell systems to (1) characterize leukocyte binding to normal control and autologous endothelial cells, (2) determine whether sex hormones influence leukocyte-endothelial cell adhesion, a question that is particularly relevant to Takayasu arteritis, and (3) assess the role of haptoglobin in stimulating angiogenesis. An epidemiologic analysis of patients with WG has continued to evaluate environmental factors, such as inhalant exposure and patient clusters.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Intramural Research (Z01)
Project #
1Z01AI000213-12
Application #
3790687
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
12
Fiscal Year
1992
Total Cost
Indirect Cost
City
State
Country
United States
Zip Code
Yamashita, Kouhei; Choi, Uimook; Woltz, Patricia C et al. (2004) Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells. Blood 103:3986-8
Kottilil, S; Shin, K; Planta, M et al. (2004) Expression of chemokine and inhibitory receptors on natural killer cells: effect of immune activation and HIV viremia. J Infect Dis 189:1193-8
Langford, Carol A; Talar-Williams, Cheryl; Barron, Karyl S et al. (2003) Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 114:463-9
Langford, Carol A; Sneller, Michael C (2003) Biologic therapies in the vasculitides. Curr Opin Rheumatol 15:3-10
Robinson, Michael R; Lee, Susan S; Sneller, Michael C et al. (2003) Tarsal-conjunctival disease associated with Wegener's granulomatosis. Ophthalmology 110:1770-80
Summers, Ronald M; Aggarwal, Neil R; Sneller, Michael C et al. (2002) CT virtual bronchoscopy of the central airways in patients with Wegener's granulomatosis. Chest 121:242-50
Langford, C A; Sneller, M C (2001) Update on the diagnosis and treatment of Wegener's granulomatosis. Adv Intern Med 46:177-206
Langford, C A; Talar-Williams, C; Sneller, M C (2000) Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 43:1836-40
Sneller, M C (2000) Cystitis, bladder cancer, and myelodysplasia in patients with Wegener's granulomatosis: comment on the article by Reinhold-Keller et al. Arthritis Rheum 43:2853-5
Langford, C A; Talar-Williams, C; Barron, K S et al. (1999) A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 42:2666-73